Daiichi Sankyo: Essential Hypertension trials

The registry lists 22 Essential Hypertension studies with Daiichi Sankyo as lead sponsor. 0 are open to participants now and 8 have results posted.

Phase 2 1Phase 3 16Phase 4 4No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Parallel-Group Comparison of Olmesartan (OLM), Amlodipine (AML) and Hydrochlorothiazid (HCTZ) in HypertensionCompletedNCT00923091Phase 3Results posted
• Hydrochlorothiazide as add-on to Olmesartan/Amlodipine in HypertensionCompletedNCT00902538Phase 3Results posted
• Efficacy and Safety of Olmesartan Medoxomil in Stage 1 and 2 Essential HypertensionCompletedNCT00890591Phase 4Results posted
• Calcium Channel Blockers (CCBs) or Diuretics as an Add-on to Olmesartan Medoxomil in HypertensionCompletedNCT00858702Phase 4Results posted
• Olmesartan Medoxomil Versus Losartan in Patients With HypertensionCompletedNCT00857285Phase 3Results posted
• Combination of Olmesartan and Hydrochlorothiazide in Essential HypertensionCompletedNCT00430950Phase 3Results posted
• Use of the Combination of Olmesartan and Hydrochlorothiazide in Essential HypertensionCompletedNCT00430508Phase 3Results posted
• Olmesartan and an add-on Treatment in Patients With Mild to Moderate HypertensionCompletedNCT00311155Phase 4Results posted
• Study of CS-3150 in Patients With Essential HypertensionCompletedNCT02890173Phase 3
• Study of CS-3150 Compared to Olmesartan in Patients With Essential HypertensionCompletedNCT02848170Not applicable
• Long-term Study of CS-3150 as Monotherapy or in Combination With Other Antihypertensive Drug in Japanese Patients With Essential HypertensionCompletedNCT02722265Phase 3
• A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Hypertensive SubjectsCompletedNCT02345044Phase 2
• Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Combination Therapy in Patients With Hypertension Not Controlled With Olmesartan Medoxomil and Hydrochlorothiazide Combination TherapyCompletedNCT01838850Phase 3
• The Confirmatory Olmesartan Plaque Regression StudyTerminatedNCT01132768Phase 4
• Evaluation of the Additional Efficacy, and Safety of Olmesartan Medoxomil 20mg / Hydrochlorothiazide 12.5mg in the Treatment of Chinese Patients With Mild to Moderate Essential HypertensionCompletedNCT00872586Phase 3
• Olmesartan Medoxomil Versus Losartan Potassium in Patients With Mild to Moderate Essential HypertensionCompletedNCT00856271Phase 3
• Olmesartan Medoxomil Versus Losartan in Elderly and Very ElderlyCompletedNCT00751751Phase 3
• Olmesartan as an add-on to Amlodipine in HypertensionCompletedNCT00220233Phase 3
• Amlodipine as add-on to Olmesartan in HypertensionCompletedNCT00220220Phase 3
• Olmesartan Medoxomil in AtherosclerosisCompletedNCT00185185Phase 3
• Olmesartan in Essential HypertensionCompletedNCT00185172Phase 3
• Olmesartan Medoxomil in Hypertension and Renal ImpairmentCompletedNCT00151827Phase 3